Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death

C Bradley Hare; Mai P Vu; Carl Grunfeld; Harry W Lampiris

doi:10.1086/344179

Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death

Clin Infect Dis. 2002 Nov 15;35(10):e111-2. doi: 10.1086/344179. Epub 2002 Oct 25.

Authors

C Bradley Hare¹, Mai P Vu, Carl Grunfeld, Harry W Lampiris

Affiliation

¹ Division of Infectious Diseases, University of California, San Francisco, California 94110, USA. [email protected]

PMID: 12410494
DOI: 10.1086/344179

Abstract

We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.

Publication types

Case Reports

MeSH terms

Aged
Drug Interactions
HIV Protease Inhibitors / adverse effects
HIV Protease Inhibitors / therapeutic use
Humans
Hypolipidemic Agents / adverse effects
Hypolipidemic Agents / therapeutic use
Male
Mortality
Nelfinavir / adverse effects*
Nelfinavir / therapeutic use
Rhabdomyolysis / drug therapy
Rhabdomyolysis / mortality*
Simvastatin / adverse effects*
Simvastatin / therapeutic use

Substances

HIV Protease Inhibitors
Hypolipidemic Agents
Simvastatin
Nelfinavir